To direct the Comptroller General of the United States to conduct a study on how direct-to-consumer pharmaceutical advertising negatively impacts drug costs to consumers, and for other purposes.

United States117th CongressHR-4278House of Representatives
Updated: Jul 1, 2021

Summary

This bill requires the Government Accountability Office to study and report on how direct-to-consumer pharmaceutical advertising negatively impacts drug costs to consumers.

Bill texts

Available versions
Introduced (House)View official text

1 version available

All available records shown.

Timeline

  1. Introduced in House

  2. Referred to the House Committee on Energy and Commerce.

    House of Representatives

  3. Referred to the Subcommittee on Health.

    House of Representatives

All available records shown.